We’re tackling the world’s toughest health challenges
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Healthcare areas include: Oncology, Immunology, Neuroscience and Cardiopulmonary.
Johnson & Johnson MedTech innovates at the intersection of biology and technology. With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex health challenges. Healthcare areas include: Cardiovascular, Orthopaedics, Surgery and Vision.
Innovating in healthcare
-
What is wAIHA?
Warm autoimmune hemolytic anemia (wAIHA) causes fatigue so profound, it can limit the lives of people who have the condition. Learn more about this rare disease and Johnson & Johnson’s clinical research and ongoing commitment to patients. -
What you need to know about Johnson & Johnson’s second-quarter 2026 earnings report
Check out this infographic breakdown of the company’s second-quarter performance, with highlights from its Innovative Medicine and MedTech businesses. -
What is acute myeloid leukemia?
It’s the most common type of acute leukemia in adults, yet it has the lowest survival rate of all leukemias. Learn more about this difficult-to-treat blood cancer and why Johnson & Johnson is on a mission to deliver better treatment options.
-
The Johnson & Johnson Institute helps HCPs learn new surgery skills—here’s how
From suturing to robotics system training, the Johnson & Johnson Institute is bringing surgical education to busy HCPs so they can deliver safe, effective care. -
The IBD resource many patients say they can’t live without
Inflammatory bowel disease (IBD) is often described as an “invisible illness” due to symptoms that aren’t always apparent to others. But for the millions living with the disease, the impact goes beyond physical symptoms. Learn how Johnson & Johnson is helping create a patient community for those dealing with the heavy psychological toll of IBD.
Learn more about how we are innovating
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
Giving the gift of sight
In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.
5 things we now know about plaque psoriasis
Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists.
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.